DK1040838T3 - Stabil vandig opløsning af 3-(1-oxo-1,3-dihydroisoindol-2-yl )piperidin-2,6-dion - Google Patents

Stabil vandig opløsning af 3-(1-oxo-1,3-dihydroisoindol-2-yl )piperidin-2,6-dion

Info

Publication number
DK1040838T3
DK1040838T3 DK00104208T DK00104208T DK1040838T3 DK 1040838 T3 DK1040838 T3 DK 1040838T3 DK 00104208 T DK00104208 T DK 00104208T DK 00104208 T DK00104208 T DK 00104208T DK 1040838 T3 DK1040838 T3 DK 1040838T3
Authority
DK
Denmark
Prior art keywords
dihydroisoindol
dione
piperidine
oxo
aqueous solution
Prior art date
Application number
DK00104208T
Other languages
Danish (da)
English (en)
Inventor
Tieno Dr Germann
Heinrich Kugelmann
Original Assignee
Gruenenthal Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19914621A external-priority patent/DE19914621C2/de
Application filed by Gruenenthal Gmbh filed Critical Gruenenthal Gmbh
Application granted granted Critical
Publication of DK1040838T3 publication Critical patent/DK1040838T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/16—Central respiratory analeptics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Rheumatology (AREA)
  • Molecular Biology (AREA)
  • Otolaryngology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK00104208T 1999-03-31 2000-03-01 Stabil vandig opløsning af 3-(1-oxo-1,3-dihydroisoindol-2-yl )piperidin-2,6-dion DK1040838T3 (da)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19914621A DE19914621C2 (de) 1997-10-06 1999-03-31 Stabile wässrige Lösung von EM 12

Publications (1)

Publication Number Publication Date
DK1040838T3 true DK1040838T3 (da) 2003-05-26

Family

ID=7903088

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00104208T DK1040838T3 (da) 1999-03-31 2000-03-01 Stabil vandig opløsning af 3-(1-oxo-1,3-dihydroisoindol-2-yl )piperidin-2,6-dion

Country Status (26)

Country Link
US (1) US6306879B1 (no)
EP (1) EP1040838B1 (no)
JP (1) JP2000290180A (no)
KR (1) KR20010006930A (no)
CN (1) CN1270027A (no)
AR (1) AR023199A1 (no)
AT (1) ATE235256T1 (no)
AU (1) AU766250B2 (no)
BR (1) BR0001112A (no)
CA (1) CA2302886A1 (no)
CO (1) CO4970704A1 (no)
DE (1) DE50001522D1 (no)
DK (1) DK1040838T3 (no)
ES (1) ES2194640T3 (no)
HK (1) HK1033645A1 (no)
HU (1) HUP0001312A2 (no)
IL (1) IL135340A0 (no)
NO (1) NO20001658L (no)
NZ (1) NZ503428A (no)
PE (1) PE20001597A1 (no)
PL (1) PL339336A1 (no)
PT (1) PT1040838E (no)
RU (1) RU2238727C2 (no)
SI (1) SI1040838T1 (no)
SK (1) SK4632000A3 (no)
ZA (1) ZA200001618B (no)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7268148B2 (en) * 1999-05-20 2007-09-11 Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enzymes
DE19957342A1 (de) * 1999-11-29 2001-05-31 Gruenenthal Gmbh Verfahren zur Behandlung und/oder Prophylaxe von IL-12-bedingten Erkrankungen
EP1389203B8 (en) 2001-02-27 2010-03-10 The Governement of the United States of America, represented by The Secretary Department of Health and Human services Analogs of thalidomide as angiogenesis inhibitors
CA2449671A1 (en) * 2001-06-06 2002-12-12 The Regents Of The University Of Michigan Compositions and methods for use against acne-induced inflammation and dermal matrix-degrading enyzmes
US7153867B2 (en) * 2001-08-06 2006-12-26 Celgene Corporation Use of nitrogen substituted thalidomide analogs for the treatment of macular degenerator
US8952895B2 (en) 2011-06-03 2015-02-10 Apple Inc. Motion-based device operations
BRPI0414497A (pt) 2003-09-17 2006-11-14 Us Gov Health & Human Serv análogos de talidomida
US8927725B2 (en) 2011-12-02 2015-01-06 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Thio compounds

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2098505T3 (es) 1991-04-17 1997-05-01 Gruenenthal Chemie Nuevos derivados de la talidomida, su procedimiento de preparacion y composiciones farmaceuticas que los contienen.
US5629327A (en) * 1993-03-01 1997-05-13 Childrens Hospital Medical Center Corp. Methods and compositions for inhibition of angiogenesis
DE19743968C2 (de) 1997-10-06 2002-07-11 Gruenenthal Gmbh Intravenöse Applikationsform von Thalidomid zur Therapie immunologischer Erkrankungen

Also Published As

Publication number Publication date
CO4970704A1 (es) 2000-11-07
PE20001597A1 (es) 2001-01-20
DE50001522D1 (de) 2003-04-30
HK1033645A1 (en) 2001-09-14
AU2420400A (en) 2000-10-05
HUP0001312A2 (en) 2001-03-28
ATE235256T1 (de) 2003-04-15
BR0001112A (pt) 2001-08-21
PT1040838E (pt) 2003-08-29
US6306879B1 (en) 2001-10-23
NZ503428A (en) 2001-08-31
RU2238727C2 (ru) 2004-10-27
NO20001658D0 (no) 2000-03-30
SK4632000A3 (en) 2000-10-09
KR20010006930A (ko) 2001-01-26
AU766250B2 (en) 2003-10-09
SI1040838T1 (en) 2003-08-31
PL339336A1 (en) 2000-10-09
CA2302886A1 (en) 2000-09-30
JP2000290180A (ja) 2000-10-17
IL135340A0 (en) 2001-05-20
NO20001658L (no) 2000-10-02
EP1040838B1 (de) 2003-03-26
AR023199A1 (es) 2002-09-04
EP1040838A1 (de) 2000-10-04
ES2194640T3 (es) 2003-12-01
HU0001312D0 (en) 2000-06-28
ZA200001618B (en) 2000-10-25
CN1270027A (zh) 2000-10-18

Similar Documents

Publication Publication Date Title
DK1129088T3 (da) Krystallinsk form af (R)-2-[[[3-methyl-4-(2,2,2-trifluorethoxy)-2-pyridin-yl]methyl]sulfinyl]-1H-ben
DE60045168D1 (de) Kombinationspräparate enthaltend (E)-7-Ä4-(4-fluorophenyl)-6-isopropyl-2-Ämethyl(methylsulfonyl)aminoÜpyrimidin-5-ylÜ(3r,5s)-3,5-dihydroxyhept-6-enoic Säure
FR12C0036I2 (fr) Derives de pyrimidines inhibiteurs de vih
ATE299866T1 (de) Piperidinderivate verwendbar als ccr5 antagonisten
DK1216239T3 (da) Antagonister af piperazin-derivater AS 5-HT1B
EE9900053A (et) 4-(5-metüül-3-fenüülisoksasool-4-üül)benseensulfoonamiidi kristalliline vorm
ATE312099T1 (de) 1,4-dihydropyridine als bradykininantagonisten
DE60105996D1 (de) Konzentrierte lösungen von carvedilol
DK1040838T3 (da) Stabil vandig opløsning af 3-(1-oxo-1,3-dihydroisoindol-2-yl )piperidin-2,6-dion
ATE289478T1 (de) Ektoparasitizide wässrige suspensionsformulierungen von spinosynen
DK1210085T3 (da) Farmaceutiske oplösninger af levosimendan
IS7343A (is) N-(3-bútýn-1-ýl) N-hýdroxý-þvagefni
DK1254118T3 (da) Substituerede 1,2,3,4-tetrahudroquinolin-2-carboxylsyrederivater
DE60132961D1 (de) Unabhängige Initialisierung von Arbitern und Agenten, um verzögerte Agent-Initialisierung zu ermöglichen
DK1165138T3 (da) Programmeret, kontrolleret ovarial stimulationsprotokol ved anvendelse af orale svangerskabsforebyggende midler
DK1231933T3 (da) Vandig oplösningsformulering af alfa-interferon
DE60007293D1 (de) Stabile, eine silikonkomponente enthaltende wässrige zusammensetzungen
IS6215A (is) Að mestu leyti kristallað form af melagatrani
DE60000343D1 (de) Stabilisierung von isothiazolonen
DK0856513T3 (da) Thalidomidanaloge forbindelser fra gruppen piperidin-2,6-dioner
ID28397A (id) Struktur alat penstabil
DE60026931D1 (de) Ausrichtung von Ausdrucken
ATE262517T1 (de) Thiopyranderivate as mmp-inhibitoren
BR9707394A (pt) Derivados de ácido 4-(benzo-1,3-dioxolil) pirrolidino-3-carboxílico como antagonistas endotelina
ATE315025T1 (de) Ethansulfonyl-piperidin-derivate